03/01/2023 - 07:00

Radiopharm to begin US trials of cancer drug after FDA tick

03/01/2023 - 07:00


Save articles for future reference.

Radiopharm Theranostics has been given the keys to the United States outpatient clinics to begin imaging trials of patients with pancreatic cancer after receiving the tick of approval from the US Food and Drug Administration for its cancer-seeking peptide.The USFDA has granted Radiopharm investigational new drug approval which will allow the company to test its patented RAD301 integrin technology in the real world.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options